LysaKare is a medicine used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide. LysaKare is for use in adults and contains the active substances arginine and lysine.
Therapeutic Indication
### Therapeutic indication LysaKare is indicated for reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
Therapeutic Area (MeSH)
ATC Code
V03AF11
ATC Item
arginine and lysine
Pharmacotherapeutic Group
Detoxifying agents for antineoplastic treatment
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| L-arginine hydrochloride | N/A | L-arginine |
| L-lysine hydrochloride | N/A | 赖氨酸 |
EMA Name
LysaKare
Medicine Name
LysaKare
Aliases
N/A
